Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Subjects With Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma

Trial Profile

A Randomized Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Subjects With Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Cisplatin; Fluorouracil
  • Indications Adenocarcinoma; Oesophageal cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 648
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 20 Jan 2024 Results of exploratory biomarker analysis (n=191) of Nivolumab (NIVO) plus chemotherapy or ipilimumab vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma presented at the 2024 Gastrointestinal Cancers Symposium
    • 20 Jan 2024 Results assessing quality-adjusted time without symptoms and toxicity (Q-TWiST) analysis comparing nivolumab plus ipilimumab or nivolumab plus chemotherapy versus CT in patients with advanced esophageal squamous cell carcinoma presented at the 2024 Gastrointestinal Cancers Symposium
    • 23 Mar 2023 According to an Ono Pharmaceutical media release, the company announced that Ono Pharma Korea Co received the additional approval of Opdivo on March 22, 2023 from the Ministry of Food and Drug Safety (MFDS) in South Korea, for the first-line treatment of patients with unresectable advanced or metastatic esophageal squamous cell carcinoma with tumor cell PD-L1 expression greater than or equal 1%, in the following two combination treatments: Opdivo + Yervoy and Opdivo + chemotherapy.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top